Please assess the completion status of the following clinical trial:

Trial Title: Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 3 through 16 years with a serum IgE to egg of \>= 5 kUA/L within the past 12 months\]~* Reacting to the initial baked egg OFC with dose limiting symptoms OR~* Reacting on a 2 gm egg OFC with dose limiting symptoms to a cumulative dose of 2 gm or less after passing the initial baked egg OFC~* Written informed consent from subject and/or parent/guardian~* Written assent from all subjects as appropriate~* All females of child bearing age must be using appropriate birth control~Exclusion Criteria:~* History of anaphylaxis to egg resulting in hypotension, neurological compromise or mechanical ventilation~* Chronic disease (other than asthma, atopic dermatitis, rhinitis) requiring therapy (e.g., heart disease, diabetes)~* Active eosinophilic gastrointestinal disease in the past 2 years~* Participation in any interventional study for the treatment of food allergy in the past 6 months~* Subject is on build-up phase of immunotherapy (i.e., has not reached maintenance dosing). Subjects tolerating maintenance allergen immunotherapy can be enrolled.~* Severe asthma, or uncontrolled mild or moderate asthma. More information on these exclusion criteria can be found in the protocol.~* Inability to discontinue antihistamines for initial day escalation, skin testing or OFC~* Use of omalizumab or other non-traditional forms of allergen immunotherapy (e.g., oral or sublingual) or immunomodulator therapy (not including corticosteroids) or biologic therapy (e.g. infliximab, rituximab, etc.) within the past year~* Use of Beta-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARB) or calcium channel blockers~* Use of investigational drug within 90 days or plan to use investigational drug during the study period~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Egg OIT Randomized (Type: EXPERIMENTAL): Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
- Baked Egg Randomized (Type: EXPERIMENTAL): Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive baked egg in the form of home-baked goods and safe commercial products with up to four oral food challenges as directed by the protocol.
- Egg OIT Assigned (Type: EXPERIMENTAL): Subjects who failed a baked egg oral food challenge (OFC) at baseline were assigned to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).